ImmPACT Bio Announces FDA Clearance of IND Application for Bispecific CD19/CD20 CAR T Therapy IMPT-514 for the Treatment of Refractory Systemic Lupus Erythematosus

Posted on by

Dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and potential to reset immune system No neurotoxicity and only Grade 1 cytokine release syndrome in ongoing UCLA investigator-led study in lymphoma WEST HILLS, Calif., Aug. 15, 2023 /PRNewswire/ — ImmPACT Bio USA,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.